Unipen

Health Discovery Corporation (OTC BB: HDVY), a biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets, today announced the first meeting of its fully constituted Scientific Advisory Board in Savannah, Georgia, USA, from July 30 to August 1, 2004, to discuss recent biomarker discovery successes and implement a strategy for moving these biomarkers forward through validation and into the commercial market.

"The constituency of our Scientific Advisory Board gives me an idea of what the manager of the 1927 Yankees, Miller Huggins, must have felt when he looked at his roster just prior to the World Series," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "That was arguably the greatest baseball team ever assembled. Among them Babe Ruth in the year he hit 60 homers, Lou Gehrig on first base, and Waite Hoyt pitching. It is no exaggeration to say that our Scientific Advisory Board is the biotech equivalent of the 1927 Yankees."

"Just as the 1927 Yankees were comprised of great hitters, great fielders, and great pitchers," Dr. Barnhill continued, "What made this group so exceptional was the sheer quantity of individual record setting performances and accomplishments that when combined formed a group far ahead of it's competition. Likewise, Health Discovery Corporation's Scientific Advisory Board, comprised of a Nobel Prize winning scientist, world renowned physicians, internationally recognized biomarker experts, globally experienced computer scientists and world authorities and pioneers in mathematics, is a carefully balanced team of the leading experts in each of the scientific disciplines essential to achieving successful breakthroughs in bioinformatics research."

Health Discovery Corporation's Scientific Advisory Board

Herbert A. Fritsche, Jr, Ph.D., Professor and Director of Clinical Chemistry at MD Anderson Cancer Center and a world-renowned authority on cancer biomarkers. (Chairman)

Kary Mullis, Ph.D., Nobel Prize Recipient for his invention of PCR (Polymerase Chain Reaction) which is hailed as one of the greatest scientific accomplishments of the twentieth century, one that revolutionized genetic science.

Vladimir Vapnik, Ph.D., winner of the prestigious Humboldt Research Award and one of the world's most renowned mathematicians in the area of statistical learning theory.

Isabelle Guyon, Ph.D., Vice-President of the International Unipen Foundation (IUF) and an internationally recognized expert in statistical data analysis, pattern recognition and machine learning.

Bernhard Scholkopf, Ph.D., Director at the Max Plank Institute for Biological Cybernetics in Tubingen, Germany and a leading world authority on pattern recognition and machine learning.

Thomas A. Stamey, M.D., Professor and the Founding Chairman of the Department of Urology at Stanford University School of Medicine, and considered to be the single most revered urologist and prostate cancer expert in the world.

Ramananda K. Madyastha, M.D., Ph.D., recipient of the Raja Ravi Sher Singh of Kalsia Memorial Cancer Research prize for outstanding contributions in the field of cancer research.

Ken Welsh, M.D., Professor of Clinical Genomics, Royal Brompton Hospital and Imperial College, London, England and internationally recognized for his accomplishments in the application of modern molecular diagnostic testing and Clinical Genomics.

Tin-Chuen Yeung, Ph.D., MBA, Pharmacologist and experienced researcher in biotechnology; former Director of Strategy & Business Development for the Biosciences Division at Baxter International, Inc. and now admitted to practice patent law before the United States Patent Bar.

Dr. Barnhill stated, "The 1927 Yankees were more than the accomplishments of each of the players. They represented TEAM in every sense of the word and the company they shared in the dugout made these great players even greater," Dr. Barnhill continued, "I believe this same level of success will be accomplished when the incredible natural synergies of our TEAM of world class scientific experts come together, face to face, with a goal of accomplishing breakthrough scientific discoveries."

Recent Health Discovery Corporation biomarker discovery contracts include:

Health Discovery Corporation (www.healthdiscoverycorp.com) is a systems biology oriented biomarker and pathway discovery company, which provides any and all aspects of "First Phase" biomarker discovery. This includes expert assessment of the clinical problem, determination of the clinical trial set-up, the proper selection and procurement of high quality specimens for analysis, an analytical evaluation of the specimens through laboratory tests to produce the relevant accurate clinical data, and the mathematical evaluation of the data using state-of-the-art computational tools to produce an accurate identification of the important genes and proteins and the pathways in which they interact. Health Discovery Corporation was established to provide both pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September 2003, the Company has offices in Texas, Georgia, and California. For more information contact Robert S. Braswell IV of Health Discovery Corporation +1-866-953-9031 or Info@healthdiscoverycorp.com.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

More information: http://www.healthdiscoverycorp.com

Contact: Robert S. Braswell IV Health Discovery Corporation +1-866-953-9031 Info@healthdiscoverycorp.com